2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related
  5. IL-6 Isoform
  6. IL-6 Inhibitor

IL-6 Inhibitor

IL-6 Inhibitors (75):

Cat. No. Product Name Effect Purity
  • HY-11109
    Resatorvid
    		Inhibitor 99.95%
    Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
  • HY-102084
    LMT-28
    		Inhibitor 98.93%
    LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.
  • HY-110133
    JTE-607
    		Inhibitor 99.27%
    JTE-607, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively. Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607.
  • HY-171034
    PQA-18
    		Inhibitor 99.62%
    PQA-18 is a unique PAK2 inhibitor (IC50: 10 nM). PQA-18 has immunosuppressing effects. PQA-18 suppresses IL2, IL4, IL6, and TNFα. PQA-18 inhibits the population of a subset of regulatory T cells and the immunoglobulin (Ig) production against T cell-dependent antigens as well as alleviates dermatitis in mice.
  • HY-170621
    STAT1/3-IN-1
    		Inhibitor
    STAT1/3-IN-1 (Compound 6k) is a STAT1/3 phosphorylation inhibitor. STAT1/3-IN-1 inhibits the phosphorylation and nuclear translocation of STAT1/3. STAT1/3-IN-1 also inhibits inflammatory enzymes iNOS and COX-2. STAT1/3-IN-1 demonstrates anti-inflammatory effect (reduction of pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α) without significant cytotoxicity.
  • HY-B1402
    Hydrocortisone hemisuccinate
    		Inhibitor 99.83%
    Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a glucocorticoid, is an orally active steroidal anti-inflammatory agent (SAID) with anti-inflammatory and immunomodulatory activities. Hydrocortisone hemisuccinate inhibits the bioactivity of IL-6 and IL-3 with IC50 values of 6.7 and 21.4 μM, respectively. Hydrocortisone hemisuccinate can be used in the study of ulcerative colitis (UC) and recurrent oral ulcers.
  • HY-15614
    SC144
    		Inhibitor 99.48%
    SC144 is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 shows potent inhibition of gp130 ligand-triggered signaling. SC144 induces apoptosis in human ovarian cancer cells.
  • HY-N0633
    Muscone
    		Inhibitor ≥98.0%
    Muscone is the main active monomer of traditional Chinese medicine musk. Muscone inhibits NF-κB and NLRP3 inflammasome activation. Muscone remarkably decreases the levels of inflammatory cytokines (IL-1β, TNF-α and IL-6), and ultimately improves cardiac function and survival rate.
  • HY-117235
    Diallyl Trisulfide
    		Inhibitor
    Diallyl Trisulfide is an orally active anticancer agent that can be isolated from garlic. Diallyl Trisulfide has the ability to induce apoptosis and exhibits anticancer, anti-inflammatory, antioxidant, and antibacterial activities. Diallyl Trisulfide can be used to study a variety of cancers, including liver, colon and prostate cancer.
  • HY-N0619
    Mulberroside A
    		Inhibitor 99.86%
    Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory antiapoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC50 of 53.6 μM.
  • HY-P9916
    Sarilumab
    		Inhibitor 98.37%
    Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis.
  • HY-15509A
    Semapimod tetrahydrochloride
    		Inhibitor 98.43%
    Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. Semapimod tetrahydrochloride inhibits TLR4 signaling (IC50≈0.3 μM). Semapimod tetrahydrochloride inhibits p38 MAPK and nitric oxide production in macrophages. Semapimod tetrahydrochloride has potential in a variety of inflammatory and autoimmune disorders.
  • HY-101019
    Ossirene
    		Inhibitor ≥98.0%
    Ossirene (AS101), an immunomodulatory tellurium compound, is a potent IL-1β inhibitor. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene potently inhibits Caspase-1 and is used for the autoimmune diseases and certain malignancies.
  • HY-113509
    Lipoxin A4
    		Inhibitor 98.00%
    Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM.
  • HY-P3042
    Chymostatin
    		Inhibitor ≥99.0%
    Chymostatin is a SARS-CoV-2 Mpro inhibitor. Chymostatin up-regulates endocan and inhibits NF-κBp65 activity. Chymostatin reduces proinflammatory cytokines (IL-1β and IL-6) and HMGB1. Chymostatin shows protective effects against Paraquat-induced acute lung injury. Chymostatin exhibits anticancer activity against lung cancer.
  • HY-P1110
    AF12198
    		Inhibitor 99.90%
    AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC50=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC50=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo.
  • HY-107390
    AX-024
    		Inhibitor 99.29%
    AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
  • HY-15790
    Elobixibat
    		Inhibitor 99.91%
    Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC50 value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
  • HY-N0212
    Peimine
    		Inhibitor 99.43%
    Peimine (Verticine; Dihydroisoimperialine) is an orally active natural product. Peimine has anti-inflammatory, analgesic and cough relieving effects. Peimine can be used in cancer and inflammation related research.
  • HY-N0604
    Ginsenoside Rh1
    		Inhibitor ≥98.0%
    Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.